1. Market Research
  2. > Pharmaceutical Market Trends
  3. > Sirtris Pharmaceuticals, Inc. – Product Pipeline Review – 2013

Sirtris Pharmaceuticals, Inc. – Product Pipeline Review – 2013

  • May 2013
  • -
  • Global Markets Direct
  • -
  • 32 pages

Sirtris Pharmaceuticals, Inc. – Product Pipeline Review – 2013

Summary

Global Market Direct’s pharmaceuticals report, “Sirtris Pharmaceuticals, Inc. - Product Pipeline Review - 2013” provides data on the Sirtris Pharmaceuticals, Inc.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Sirtris Pharmaceuticals, Inc.’s corporate website, SEC filings, investor presentations and featured press releases, both from Sirtris Pharmaceuticals, Inc. and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Sirtris Pharmaceuticals, Inc. - Brief Sirtris Pharmaceuticals, Inc. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Sirtris Pharmaceuticals, Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Sirtris Pharmaceuticals, Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Sirtris Pharmaceuticals, Inc.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Sirtris Pharmaceuticals, Inc.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Sirtris Pharmaceuticals, Inc. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Sirtris Pharmaceuticals, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Sirtris Pharmaceuticals, Inc..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Sirtris Pharmaceuticals, Inc. and identify potential opportunities in those areas.

Table Of Contents

Sirtris Pharmaceuticals, Inc. - Product Pipeline Review - 2013
Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4
Sirtris Pharmaceuticals, Inc. Snapshot 5
Sirtris Pharmaceuticals, Inc. Overview 5
Key Information 5
Key Facts 5
Sirtris Pharmaceuticals, Inc. - Research and Development Overview 6
Key Therapeutic Areas 6
Sirtris Pharmaceuticals, Inc. - Pipeline Review 8
Pipeline Products by Stage of Development 8
Pipeline Products - Monotherapy 9
Sirtris Pharmaceuticals, Inc. - Pipeline Products Glance 10
Sirtris Pharmaceuticals, Inc. Clinical Stage Pipeline Products 10
Phase I Products/Combination Treatment Modalities 10
Sirtris Pharmaceuticals, Inc. - Early Stage Pipeline Products 11
Pre-Clinical Products/Combination Treatment Modalities 11
Sirtris Pharmaceuticals, Inc. - Drug Profiles 12
SRT-1720 12
Product Description 12
Mechanism of Action 12
RandD Progress 12
SRT-2379 13
Product Description 13
Mechanism of Action 13
RandD Progress 13
SRT-3025 15
Product Description 15
Mechanism of Action 15
RandD Progress 15
Sirtris Pharmaceuticals, Inc. - Pipeline Analysis 17
Sirtris Pharmaceuticals, Inc. - Pipeline Products by Therapeutic Class 17
Sirtris Pharmaceuticals, Inc. - Pipeline Products by Route of Administration 18
Sirtris Pharmaceuticals, Inc. - Pipeline Products By Mechanism of Action 19
Sirtris Pharmaceuticals, Inc. - Discontinued Pipeline Products 20
Discontinued Pipeline Product Profiles 20
resveratrol 20
Sirtris Pharmaceuticals, Inc. - Locations And Subsidiaries 21
Head Office 21
Financial Deals Landscape 22
Sirtris Pharmaceuticals, Inc., Deals Summary 22
Sirtris Pharmaceuticals, Inc., Pharmaceuticals and Healthcare, Deal Details 23
Venture Financing 23
Sirtris Pharma Raises US$36 Million In Series C-1 Financing Round 23
Licensing Agreements 24
Sirtris Pharma Enters Into Licensing Agreement With Harvard University 24
Sirtris Pharma Enters Into Licensing Agreement With Robarts Research Institute 25
Sirtris Pharma Enters Into Licensing Agreement With Massachusetts Institute Of Technology For SIRT1 26
Equity Offering 27
Sirtris Pharma Completes IPO US$69 Million 27
Acquisition 29
GlaxoSmithKline Acquires Sirtris Pharma 29
Appendix 31
Methodology 31
Coverage 31
Secondary Research 31
Primary Research 31
Expert Panel Validation 31
Contact Us 32
Disclaimer 32



List of Tables

Sirtris Pharmaceuticals, Inc., Key Information 5
Sirtris Pharmaceuticals, Inc., Key Facts 5
Sirtris Pharmaceuticals, Inc. - Pipeline by Indication, 2013 7
Sirtris Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2013 8
Sirtris Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2013 9
Sirtris Pharmaceuticals, Inc. - Phase I, 2013 10
Sirtris Pharmaceuticals, Inc. - Pre-Clinical, 2013 11
Sirtris Pharmaceuticals, Inc. - Pipeline By Therapeutic Class, 2013 17
Sirtris Pharmaceuticals, Inc. - Pipeline By Route of Administration, 2013 18
Sirtris Pharmaceuticals, Inc. - Pipeline Products By Mechanism of Action, 2013 19
Sirtris Pharmaceuticals, Inc. - Discontinued Pipeline Products, 2013 20
Sirtris Pharmaceuticals, Inc., Deals Summary 22
Sirtris Pharma Raises US$36 Million In Series C-1 Financing Round 23
Sirtris Pharma Enters Into Licensing Agreement With Harvard University 24
Sirtris Pharma Enters Into Licensing Agreement With Robarts Research Institute 25
Sirtris Pharma Enters Into Licensing Agreement With Massachusetts Institute Of Technology For SIRT1 26
Sirtris Pharma Completes IPO US$69 Million 27
GlaxoSmithKline Acquires Sirtris Pharma 29



List of Figures

Sirtris Pharmaceuticals, Inc. - Pipeline by Indication, 2013 7
Sirtris Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2013 8
Sirtris Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2013 9
Sirtris Pharmaceuticals, Inc. - Pipeline By Therapeutic Class, 2013 17

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
cAMP and cAMP Inhibited cGMP 3%,5% Cyclic Phosphodiesterase 10A (Phosphodiesterase 10A1 or Phosphodiesterase 10A7 or PDE10A or EC 3.1.4.17 or EC 3.1.4.35) - Pipeline Review, H2 2016

cAMP and cAMP Inhibited cGMP 3%,5% Cyclic Phosphodiesterase 10A (Phosphodiesterase 10A1 or Phosphodiesterase 10A7 or PDE10A or EC 3.1.4.17 or EC 3.1.4.35) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

cAMP and cAMP Inhibited cGMP 3',5' Cyclic Phosphodiesterase 10A (Phosphodiesterase 10A1 or Phosphodiesterase 10A7 or PDE10A or EC 3.1.4.17 or EC 3.1.4.35) - Pipeline Review, H2 2016 Summary Global Markets ...

Interleukin 1 Beta (IL 1 Beta or Catabolin or IL1B) - Pipeline Review, H2 2016

Interleukin 1 Beta (IL 1 Beta or Catabolin or IL1B) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • July 2016
  • by Global Markets Direct

Interleukin 1 Beta (IL 1 Beta or Catabolin or IL1B) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Interleukin 1 Beta (IL 1 Beta or Catabolin or IL1B) - Pipeline Review, H2 2016’, ...

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Iduronate 2 Sulfatase (Alpha L Iduronate ...


ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.